Yttrium-90 transarterial radioembolization of primary lung cancer metastases to the liver Journal Article

   


Authors: Alexander, E. S.; Petre, E. N.; Zhao, K.; Sotirchos, V.; Namakydoust, A.; Moussa, A.; Yuan, G.; Sofocleous, C. T.; Solomon, S. B.; Ziv, E.
Article Title: Yttrium-90 transarterial radioembolization of primary lung cancer metastases to the liver
Abstract: Purpose: To assess whether yttrium-90 transarterial radioembolization (TARE) is safe and effective in the treatment of primary lung cancer metastases to the liver (LCML). Methods and Methods: This retrospective study included 57 patients with LCML who were treated with 79 TARE treatments. Histology included non–small cell lung cancer (NSCLC) (n = 27), small cell lung cancer (SCLC) (n = 17), and lung carcinoid (LC) (n = 13). Survival was calculated using Kaplan–Meier method; differences between groups were estimated using log rank test. Cox proportional hazards model was used to determine factors influencing survival. Adverse events were graded using the Society of Interventional Radiology Adverse Events Classification. Results: Median overall survival (OS) was as follows: NSCLC, 8.3 months (95% confidence interval [CI], 6.3–16.4 months); SCLC, 4.1 months (95% CI, 1.9–6.6 months); and LC, 43.5 months (95% CI, 7.8–61.4 months). For NSCLC, presence of bilobar vs unilobar disease (hazard ratio [HR], 5.24; 95% CI, 1.64–16.79; P = .002); more tumors, 2–5 vs 1 (HR, 4.88; 95% CI, 1.17–20.37; P = .003) and >5 vs 1 (HR, 3.75; 95% CI, 0.95–6.92; P = .05); and lobar vs segmental treatment (HR, 2.56; 95% CI, 0–NA; P = .002) were negative predictors of OS. For SCLC, receipt of >2 lines of chemotherapy vs ≤2 lines (HR, 3.16; 95% CI, 0.95–10.47; P = .05) was a negative predictor of OS. For LC, tumor involvement of >50% was a negative predictor of OS (HR, 3.77 × 1015; 95% CI, 0–NA; P = .002). There were 11 of 79 severe or life-threatening adverse events within 30 days (abdominal pain, altered mental status, nausea/vomiting, acalculous/aseptic cholecystitis, hyponatremia, pancreatitis, renal failure, and death from pneumonia). Conclusions: TARE has an acceptable safety profile for the treatment of LCML, with survival benefits best seen in LC tumors. © 2023 SIR
Journal Title: Journal of Vascular and Interventional Radiology
Volume: 35
Issue: 2
ISSN: 1051-0443
Publisher: Elsevier Science, Inc.  
Date Published: 2024-02-01
Start Page: 214
End Page: 225.e2
Language: English
DOI: 10.1016/j.jvir.2023.10.025
PUBMED: 37923172
PROVIDER: scopus
PMCID: PMC11323230
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85179481300&doi=10.1016%2fj.jvir.2023.10.025&partnerID=40&md5=6859bf6523481a6ced88a06a76b7acb1
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF. Corresponding MSK author is Erica S. Alexander -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Stephen Solomon
    422 Solomon
  2. Constantinos T Sofocleous
    244 Sofocleous
  3. Elena Nadia Petre
    108 Petre
  4. Etay Ziv
    111 Ziv
  5. Vlasios S Sotirchos
    53 Sotirchos
  6. Azadeh Namakydoust
    22 Namakydoust
  7. Amgad Mohamed Abdelhady Moussa
    34 Moussa
  8. Erica Alexander
    36 Alexander
  9. Ken Zhao
    35 Zhao
  10. Gavin Yuan
    3 Yuan
Related MSK Work